This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Compugen Drug Candidate Demonstrates Attenuation Of Autoimmunity And Reestablishment Of Immune Balance

Compugen Ltd. (NASDAQ: CGEN) announced today that pre-clinical findings presented at the 3rd European Congress of Immunology provide additional support for the potential of CGEN-15001 to effectively treat autoimmune disease. Mode of action studies for CGEN-15001 demonstrated both the active suppression of pathogenic immune responses and the reestablishment of immune balance by increasing anti-inflammatory mediators and promoting inducible regulatory T cells (iTregs). Modulation of iTregs is considered an extremely promising approach for treatment of autoimmunity and cancer, and therefore has been the focus of intense industry and academic research in recent years.

These results were included in a presentation focused on CGEN-15001 by Dr. Joseph R. Podojil, a Research Assistant Professor in the laboratory of Professor Stephen Miller at Northwestern University, at the 3rd European Congress of Immunology held last week in Glasgow, U.K. In his talk, Dr. Podojil presented data supporting multiple modes by which CGEN-15001 appears to mitigate aberrant immune function leading to autoimmunity. In addition to the data supporting its promotion of iTregs, which was disclosed for the first time at the congress, Dr. Podojil discussed CGEN-15001’s previously reported ability to prevent autoreactive inflammatory immune cell infiltration to the central nervous system as well as its immunomodulatory activity, thereby both turning off pro-inflammatory immune cells and promoting immunoregulatory immune responses.

"The very promising results being presented by our collaborators at Northwestern University demonstrate that CGEN-15001 may provide an effective therapy for restoring immune system balance and proper function in the presence of autoimmune disease,” said Dr. Anat Cohen-Dayag, Compugen’s President and CEO. "Preclinical studies of CGEN-15001 have shown excellent therapeutic effects in established models of both multiple sclerosis and rheumatoid arthritis. Based on the results to date and our recent understandings of its mode of action, we believe that CGEN-15001 has the potential to emerge as an efficacious and safe disease modifying therapy for these and other autoimmune diseases."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs